Filing Flows

Filing Flows › Companies › Citius Pharmaceuticals › Cash flow

Citius Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$8.7M in Q3 FY26 · −$34.9M over twelve months

Operating cash flow−$8.7M
Free cash flow−$8.7M
Cash conversion cycle2625 days

Analysis

In Q3 FY26, Citius Pharmaceuticals generated −$8.7M of operating cash flow. That is $3.3M less than in Q3 FY25 (−$5.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$34.9M; the largest uses were operating cash flow ($34.9M); besides operations, cash came from shares issued ($41.1M), other financing ($17.5M); the cash balance rose by $10.9M.

Operating cash flow was −$8.7M against net income of −$11.9M. The largest differences: stock-based pay +$3.8M, employee-related liabilities −$1.7M, payables −$1.4M.

Its cash conversion cycle was 2625 days (receivables 54 + inventory 4189 − payables 1618).

Free cash flow

Citius Pharmaceuticals: free cash flow by quarterCitius Pharmaceuticals: free cash flow by quarter−$5.9MQ4 FY24−$4.7MQ1 FY25−$4.5MQ2 FY25−$5.4MQ3 FY25−$11.9MQ4 FY25−$13.0MQ1 FY26−$1.3MQ2 FY26−$8.7MQ3 FY26
Operating cash flow less capital spending.
Citius Pharmaceuticals: operating cash flow against capital spendingCitius Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$5.9M$0Q4 FY24−$4.7M$0Q1 FY25−$4.5M$0Q2 FY25−$5.4M$0Q3 FY25−$11.9M$0Q4 FY25−$13.0M$0Q1 FY26−$1.3M$0Q2 FY26−$8.7M$0Q3 FY26
Latest (Q3 FY26): Operating cash flow −$8.7M, Capital spending $0.

Capital allocation, year by year

Citius Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearCitius Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY21: Operating cash flow −$24.3MFY21: Net borrowing −$172KFY21: Shares issued $71.1MFY21: Capital spending −$7K$71.1MFY21FY22: Operating cash flow −$28.4MFY22FY23: Operating cash flow −$29.1MFY23: Shares issued $13.8M$13.8MFY23FY24: Operating cash flow −$28.2MFY24: Net borrowing $247KFY24: Shares issued $13.8M$14.1MFY24FY25: Operating cash flow −$26.6MFY25: Net borrowing $1.3MFY25: Shares issued $32.3M$33.6MFY25
Over these 5 years operating cash flow totalled −$136M; the largest uses were operating cash flow ($136M) and net borrowing ($172K). Cash-flow statements as filed.

Where the cash came from and went

Citius Pharmaceuticals: sources (+) and uses (−) of cash, Q3 FY26Citius Pharmaceuticals: sources (+) and uses (−) of cash, Q3 FY26Other financing$16.9MCash drawn (+) / kept (−)−$12.4MOperating cash flow−$8.7MShares issued$4.5MOther investing−$2.0MNet borrowing (+) / repaid (−)$1.8M
Citius Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 FY26Citius Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 FY26Shares issued$41.1MOperating cash flow−$34.9MOther financing$17.5MNot reconciled−$12.8MCash drawn (+) / kept (−)−$10.9M

From profit to cash

Citius Pharmaceuticals: net income to operating cash flow, Q3 FY26Citius Pharmaceuticals: net income to operating cash flow, Q3 FY26Net income−$11.9MStock-based pay$3.8MDeferred taxes−$107KInventory$34KPayables−$1.4MAccrued liabilities$13KEmployee-related liabilities−$1.7MPrepaid and other assets$345KOperating cash flow−$8.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 FY2654418916182625
Q2 FY26138619828023535

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 FY26−$8.7M$1.8M$4.5M−$12.4M−$8.7M
Q2 FY26−$1.3M—−$63K$3.1M−$1.3M
Q1 FY26−$13.0M—$20.9M−$3.5M−$13.0M
Q4 FY25−$11.9M—$15.8M$1.8M−$11.9M
Q3 FY25−$5.4M—$10.5M−$6.1M−$5.4M
Q2 FY25−$4.5M—$3.5M$1.1M−$4.5M
Q1 FY25−$4.7M—$2.6M$2.2M−$4.7M
Q4 FY24−$5.9M—$85K$14.7M−$5.9M

Citius Pharmaceuticals: income statement and cash flow

Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%. The chart follows the revenue to costs, profit and cash.

Citius Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.